Oxurion
Bookmark
ShareCopied to clipboardOxurion is a company. It is a public company in Leuven, Belgium. It was founded in 1991 and its current CEO is Thomas Graney. It is part of the Health Care sector, specifically in the Biotechnology industry.
Key facts
- city: Leuven
- country: Belgium
- employees: 42 people
- revenues: 1.1M $
- company type: public
- sector: Health Care
- industry: Biotechnology
- foundation year: 1991
- CEO: Thomas Graney
- ESG score: Try Pro to see estimate
See more facts
Extract data
Download datasets about Oxurion:
Dataset of stocks from Oxurion:
Oxurion is one of the companies in Belgium, companies in Biotechnology, companies in Health Care, companies in Leuven and 3,456,808 companies in our database.
Talking Points
- Oxurion: We're developing next-generation ophthalmic therapies
- Oxurion dedicated to developing innovative treatments to improve and better preserve vision for patients with diabetic macular edema (DME)
- Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.